CliffBio
biologic

Rabavert

Rabies Vaccine

Loss of exclusivityOctober 2009projected — 12-year biologic exclusivity estimate
CompanyBavarian Nordic A/S

Drug detail

Brand nameRabavert
Active ingredientRabies Vaccine
Strength2.5IU
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalOctober 1997
Marketing statusRx

More from Bavarian Nordic A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rabavert patent cliff — loss of exclusivity October 2009 | CliffBio